EFFICACY OF LURASIDONE IN ANTIPSYCHOTIC-NAIVE ADOLESCENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF A 6-WEEK, RANDOMIZED, PLACEBO-CONTROLLED STUDY

被引：1
|
作者：
Correll, Christoph [1 ]
Goldman, Robert [2 ]
Tocco, Michael [2 ]
Pikalov, Andrei [2 ]
Hsu, Jay [2 ]
Loebel, Antony [2 ]
机构：
[1] Hofstra North Shore LIJ Sch Med, Zucker Hillside Hosp, Hempstead, NY USA
[2] Sunovion Pharmaceut Inc, Marlborough, MA USA
来源：
SCHIZOPHRENIA BULLETIN | 2019年 / 45卷
关键词：
D O I：
10.1093/schbul/sbz018.518
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
F106
引用
收藏
页码：S293 / S294
页数：2
相关论文
共 50 条
  • [11] Long-term efficacy of lurasidone in antipsychotic-naive vs. antipsychotic-exposed adolescents with schizophrenia: Post-hoc analysis of a two year, open-label study
    Correll, C.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Loebel, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S88 - S88
  • [12] Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study
    Iyo, Masaomi
    Ishigooka, Jun
    Nakamura, Masatoshi
    Sakaguchi, Reiko
    Okamoto, Keisuke
    Mao, Yongcai
    Tsai, Joyce
    Fitzgerald, Alison
    Nosaka, Tadashi
    Higuchi, Teruhiko
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2021, 75 (07) : 227 - 235
  • [13] Efficacy and safety of lurasidone in acutely psychotic patients with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled study
    Iyo, Masaomi
    Ishigooka, Jun
    Nakamura, Masatoshi
    Sakaguchi, Reiko
    Okamoto, Keisuke
    Mao, Yongcai
    Tsai, Joyce
    Fitzgerald, Alison
    Nosaka, Tadashi
    Higuchi, Teruhiko
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2021, : 227 - 235
  • [14] Lurasidone for bipolar I depression with anxiety: Post-hoc analysis of a randomized, placebo-controlled study
    Hagi, Katsuhiko
    Shima, Hirokazu
    Inoue, Takeshi
    BIPOLAR DISORDERS, 2021, 23 : 70 - 71
  • [15] A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Risperidone in Adolescents with Schizophrenia
    Haas, Magali
    Unis, Alan S.
    Armenteros, Jorge
    Copenhaver, Margaret D.
    Quiroz, Jorge A.
    Kushner, Stuart F.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2009, 19 (06) : 611 - 621
  • [16] Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: Pooled analysis of double-blind, placebo-controlled 6-week studies
    Calisti, F.
    Costamagna, I.
    Hsu, J.
    Tocco, M.
    Pikalov, A.
    Goldman, R.
    EUROPEAN PSYCHIATRY, 2021, 64 : S166 - S166
  • [17] Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: pooled analysis of double-blind, placebo-controlled 6-week studies
    Costamagna, I.
    Calisti, F.
    Hsu, J.
    Tocco, M.
    Pikalov, A.
    Goldman, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S473 - S474
  • [18] Long-term safety and effectiveness of open-label lurasidone in antipsychotic-Naive versus previously treated adolescents with Schizophrenia: A post-hoc analysis
    Correll, Christoph U.
    Tocco, Michael
    Pikalov, Andrei
    Hsu, Jay
    Goldman, Robert
    SCHIZOPHRENIA RESEARCH, 2022, 240 : 205 - 213
  • [19] THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA: A 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY
    Goldman, Robert S.
    Findling, Robert L.
    Silva, Robert M.
    Cucchiaro, Josephine B.
    Deng, Ling
    Loebel, Antony
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2016, 55 (10): : S163 - S164
  • [20] Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia
    Marder, Stephen R.
    Eriksson, Hans
    Zhao, Yudong
    Hobart, Mary
    ACTA NEUROPSYCHIATRICA, 2020, 32 (03): : 153 - 158
12345